Five-year survival for all cancers combined was 81% in children and 87% in adolescents/ young adults. Between-country survival differences narrowed for both children and adolescents/young adults. Relative risk of death reduced significantly, by 8% in children and by 13% in adolescents/young adults, from 1995-1999 to 2000-2002. Survival improved significantly over time for acute lymphoid leukaemia and primitive neuroectodermal tumours in children and for non-Hodgkin lymphoma in adolescents/young adults.
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Introduction
About 15,000 children (age 0-14 years) and 20,000 adolescents/ young adults (age 15-24 years) are diagnosed with cancer each year in Europe. 1 Although only 1% of all cancers are diagnosed in these age groups, they have a number of characteristics that increase their impact on society:
-The prevalence of adults diagnosed with cancer before age 25 is increasing due to improving survival, and to a lesser extent, increasing cancer incidence.
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-The risk of second cancers is high in adults surviving cancer diagnosed before age 25. -Many cancer survivors diagnosed before age 25 experience sequelae in later life that require medical treatment. -European populations differ markedly in cancer survival, implying inequality of access to treatment for diseases in young people which are typically highly curable. -Survival in adolescents/young adults is worse than in children with biologically similar cancers, probably because intensive treatment protocols have been mainly developed for children.
Survival data for young Europeans (below age 25) diagnosed with cancer between 1978 and 1994 are available in various EUROCARE publications. 3, 4 The ACCIS project 5 produced survival figures for European children and adolescents <20 up to diagnosis year 1997, and substantiated the disparities in survival across Europe brought to light by EUROCARE. The present EUROCARE-4 study analyses survival and survival time trends in young Europeans diagnosed with cancer between 1995 and 2002, and also examines trends in survival differences between different European populations.
Materials and methods
Survival was analysed for 40,392 European children (age 0-14 years) and 30,187 adolescents/young adults (age 15-24 years) diagnosed with cancer during the period 1995 -2002 and followed-up at least until December 31, 2003 . All cases with a malignant neoplasm, as defined by ICD for Oncology (ICD-O-3) 6 behaviour code 3 or higher, were included. Only first tumours were analysed; 771 cases were excluded from the analysis as they were second or later primary tumours. The cases were contributed by 83 population-based cancer registries in 23 countries participating in EUROCARE-4. The countries were Denmark, Finland, Iceland, Norway and Sweden (grouped as Northern Europe); the Czech Republic and Poland (Eastern Europe); Austria, Belgium, France, Germany, the Netherlands and Switzerland (Central Europe); Italy, Malta, Portugal, Slovenia and Spain (Southern Europe); and England, Ireland, Northern Ireland, Scotland and Wales (United Kingdom (UK) and Ireland).
The registries of Denmark, Finland, Iceland, Norway, Sweden, Austria, , Malta, Slovenia, Ireland, Northern Ireland, Scotland, Wales and England cover the national entire populations. The other countries are represented by one or more local or regional registries. The general cancer registries of Saarland (Germany), Macerata, Biella and Torino (Italy), and England and Wales (UK) only contributed cases aged 15-24 years, since data from children were provided by childhood cancer registries covering the same territories. In fact eight childhood cancer registries contributed data: England and Wales; Germany; Piedmont and Marche in Italy; the Spanish Childhood Cancer Registry (Barcelona only) and Comunitat Valenciana (Castelló n and Valencia); and Bretagne and Lorraine in France. Two specialised adult French cancer registries (Cô te d'Or Haematologique and Marne-Ardennes (thyroid)) also contributed data.
Childhood cancers were classified into 12 main categories and their subgroups in the International Classification of Childhood Cancers (ICCCs) third edition. 7 However, in line with the EUROCARE protocol, skin cancers (ICCC XIe) were excluded, and only malignant cancers within the categories of intracranial and intraspinal neoplasms (III and Xa) were included. As in the previous EUROCARE studies, this meant that cases of non-malignant neoplasms such as craniopharyngioma, meningioma, ganglioglioma and teratoma were excluded. For the first time, however, pilocytic astrocytoma -the most frequent CNS cancer in children and young people -was also excluded because it has borderline behaviour code in ICD-O-3, whereas in the previous editions of ICD-O this cancer was considered malignant. Since pilocytic astrocytoma, which has a very good prognosis, was included in the earlier studies and the proportions of astrocytoma cases of unspecified subtype, which still have a malignant behaviour code, were expected to vary between European regions and registries, survival for an expanded category of astrocytoma including the 2103 children and 333 adolescents and young adults with pilocytic tumours was also analysed, so as to retain comparability between regions and earlier time periods (Tables 3 and 5 only) . In the data from the Finnish registry, astrocytomas and gliomas not otherwise specified (NOS) shared the same morphology code, and thus could not be distinguished. Therefore, Finland was excluded from the analysis of astrocytoma survival.
The registries of Denmark and Thames did not furnish ICD-O morphology codes but only ICD10 data, 8 thus for these registries it was not possible to apply the ICCC completely, and only cancers (all cancers combined, leukaemias, lymphomas and all CNS cancer combined) for which ICCC and ICD10 codes were similar were included. Cancers in adolescents/young adults were classified using both the ICCC and the ICD-O-3 classifications, because the spectrum of cancers typical of these age groups differs from that in children. The following cancers, characteristic of adolescents and young adults, were classified according to ICD-O: skin melanoma (ICD-O topography = C44, ICD-O morphology = 872-879), cervix uteri (ICD-O = C53), thyroid (ICD-O = C73.9), colon (ICD-O = C18), lung (ICD-O = C34), bone (ICD-O = C40-41) and breast (ICD-O = C50) cancers. Table 1 presents the cases by country, cancer registry, age and year of diagnosis, with main data quality indicators. The specialised registries of Calvados (digestive), Cô te d'Or (digestive), Castelló n (breast), Zurich (colon and rectum), Albacete (breast) and Palermo (breast) are not included in Table 1 as together they contributed only 10 cases. Sixty-six percent of cases were diagnosed from 1995 to 1999; 52 registries also contributed cases diagnosed from 2000 to 2002. Overall 26% of childhood cases were diagnosed below the age of 5 years; however, around 45% of the cases contributed by childhood cancer registries were under five. Overall 27% of cases were young adults, while 30-42% of the cases contributed by general cancer registries were young adults.
Only 0.4% of cases were known to registries only by death certificate or by autoptic diagnosis (these cases were excluded from the survival analyses). Overall, 95% of cases were microscopically verified. Trento (68%) had the lowest proportion of microscopically verified cases, while for five registries all cases were microscopically verified.
Three percent of live cases diagnosed in the period 1995-1998 had a follow-up of <5 years. Although for most registries <1% of cases had a follow-up <5 years, in seven registries the proportion exceeded 10%. The proportion of patients censored 'alive' with a follow-up <5 years was not available for registries which perform only passive follow-up (all UK general cancer registries except East Anglia).
Overall, 5.6% of cases had unspecified ICCC morphology. Since Denmark and Thames did not send morphology data, these registries were excluded from the analyses in which cases were classified into ICCC diagnostic groups. A total of 3.8% of cases had unspecified morphology after Denmark and Thames had been excluded.
Observed survival and relative survival were calculated with the SEER * Stat software (Release 6.3.6). 9 However, only observed survival is presented because it corresponds very closely to observed survival in young people, since deaths due to competing risks are rare. Observed survival was calculated by the actuarial method. 10 Survival is presented: for all cancers combined by country in age groups 0-14 years and 15-24 years (Figs. 1 and 2, respectively); for 15 selected (common) ICCC diagnostic categories in children (0-14 years) for Europe as a whole and by regional grouping (Table 3 ); for 15 rare cancers in children for Europe as a whole (Table 4 ) and for malignancies characteristic of 15-24-year-olds for Europe as a whole and by regional grouping (Table 5 ). For the diagnosis period 1995-1999, to which all registries contributed cases, 5-year observed survival was calculated by regional grouping. For the diagnosis period 2000-2002 survival was estimated for Europe as a whole.
To ensure survival comparability, for each cancer, the survival of children (age 0-14 years) in each regional grouping was adjusted to the age distribution of all European children diagnosed in the period 2000-2002 with that cancer. For age standardisation, three age classes were generally used (0-4, 5-9 and 10-14 years). For neuroblastoma, the age classes were <1, 1-4 and 5-14 years. For two other cancers, data are presented for a single age class: <5 years for retinoblastoma; 10-14 years for osteosarcoma. Age adjustment was not applied to patients 15-24-year-old. 
Since the nation-wide registries of the UK and Germany contributed the largest proportions of cases, survival in Europe as a whole was obtained by directly weighting the regional grouping survival estimates with factors proportional to the population in each regional grouping. This procedure assumes that the population covered by registration is representative of the country to which it belongs. The weightings employed were 5.64 1995-1999 versus 2000-2002) and case mix. In the model for children, three age classes were used (0-4, 5-9, and 10-14 years) and 10 diagnostic categories to adjust for case mix: (1) (10) other sites. In the model for adolescents and young adults, two age classes (15-19 and 20-24) were used, and the case mix categories were: (1) Hodgkin lymphomas (ICCC IIa); (2) non-Hodgkin lymphomas (ICCC IIb); (3) leukaemias (ICCC Ia, Ib); (4) testis and ovary (ICDO C62, C56.9); (5) skin melanoma (ICDO C44, 8720-8790); (6) CNS tumours (ICCC III); (7) bone (ICDO C40-41); (8) thyroid (ICDO C739); (9) soft tissues (ICDO C49) and (10) other sites. Difference in 5-year survival in relation to the four covariates such as sex, age, period of diagnosis and diagnostic category is presented as relative risks (RRs) of death. Geographic variation in survival is presented as country-specific survival estimates, using the marginal distribution of the other four covariates as common covariates. Interactions between country and diagnostic period were investigated, but were not significant. Proportionality of risk among the other covariates was assumed.
A Cox proportional hazard model 13 was also applied to each diagnostic group to estimate RR of death for 2000-2002 versus 1995-1999 , adjusting to by regional grouping, diagnosis period, sex and age. To assess changes in between-country survival differences, data from EUROCARE-3 (diagnosis period 1990-1994) and EUROCARE-4 (diagnosis period 1995-1999) were compared for cancer registries that provided data for both the periods.
Results
All cancers combined
Five-year survival estimates by country for all cancers combined diagnosed in 1995-2002 are shown in Fig. 1 (children) and Fig. 2 (adolescents/young adults). For most countries survival in children ranged between 78% and 83%. Malta and Czech Republic had lower survival (75% and 76%, respectively), which did not, however, differ significantly from mean European survival (81%). Austria had the highest survival (86%). For adolescents/young adults, 5-year survival was 87% overall, and the range was even narrower than that in children: from 84% in Northern Ireland to 92% in Iceland (neither significantly different from the European mean). As shown in Table 2 , RRs of death for all cancers combined reduced significantly, by 8% in children and by 13% in young adults, from 1995-1999 to 2000-2002. Outcomes were better for girls than for boys, but survival did not differ with age.
Childhood cancers
Five-year period survival estimates (with 95% confidence intervals (CIs)) for the entire European pool of children diagnosed in 2000-2002 are shown in Table 3 for the major diagnostic groups. For most haemopoietic cancers, 5-year survival was high (85% for lymphoid leukaemia, 82% for non-Hodgkin lymphoma, 84% for Burkitt lymphoma and 95% for Hodgkin lymphoma), although for acute myeloid leukaemia survival was only 67%. Five-year survival for CNS cancers was modest, with limited variation in relation to morphology: 62% for ependymoma, 66% for embryonal tumours, mainly medulloblastoma and other primitive neuroectodermal tumours (PNET) and 63% for astrocytoma. When pilocytic astrocytoma (49% of all astrocytomas) was included, survival for astrocytoma increased to 78%.
Five-year survival for retinoblastoma was very high at 98%. Survival was also good (89%) for nephroblastoma and other non-epithelial renal tumours, a category consisting overwhelmingly of nephroblastoma but with other renal cancers accounting for 5% of cases. For other solid tumours, survival decreased in the order osteosarcoma (77%), neuroblastoma (72%), rhabdomyosarcoma (69%), and Ewing sarcoma (67%). Five-year survival for 15 common cancers diagnosed in children in 1995-1999 is also shown, for each European regional grouping, in Table 3 . Central and Northern Europe had highest survival for most cancers; Eastern Europe had lowest survival for several cancers. The survival gap was marked for leukaemias, non-Hodgkin lymphoma, PNET and Ewing sarcoma.
Five-year survival for 15 rare cancers in children is shown in Table 4 . Survival was relatively poor for hepatic carcinoma (45%), adrenocortical carcinoma (60%) and chronic myeloproliferative disease (64%), while for the other rare malignancies survival was P70%.
3.3.
Cancer in adolescents and young adults
Five-year period survival estimates (with 95% CIs) for the European pool of adolescents and young adults diagnosed in 2000-2002 are shown in Table 5 . As with children, haemopoietic cancers were the most common, but unlike children, lymphomas were more common than leukaemias. Survival was high for Hodgkin lymphoma (93%), intermediate for nonHodgkin lymphoma (74%) and relatively low for acute myeloid leukaemia (59%) and lymphoid leukaemia (50%). Pilocytic astrocytoma accounted for 24% of astrocytoma cases in this age group; their inclusion increased survival for all astrocytomas from 56% to 64%. Gonadal germ cell cancer and skin melanoma were the second and third most common malignancies in adolescents and young adults; both had relatively high survival (97% and 92%, respectively).
Survival variation by regional grouping is shown in Table 5 . Survival was generally highest in Northern Europe and lowest in Eastern Europe.
3.4.
Survival changes over time Table 6 shows the RRs of dying from major malignancies for children diagnosed in 2000-2002 compared to those diagnosed in 1995-1999. Table 7 shows a similar comparison for adolescents and young adults diagnosed with cancers characteristic of this age range. For children, there was a significant reduction in the RRs of dying for acute lymphoid leukaemia and all CNS cancers, 1990-1994 to diagnosis period 1995-1999 . In the whisker plots, the heavy line is the median, the box represents the interquartile range and vertical line (whisker) extends from the lowest to the highest survival. Countries are represented only by registries that contributed data for both periods.
most conspicuously PNET. For adolescents and young adults, only for non-Hodgkin lymphoma was the RR significantly lower in the later period. Fig. 3 shows the ranges of 5-year country-specific survival for all cancers combined in 1990-1994 compared with those in 1995-1999 in the countries that contributed data for both the periods. 14, 4 Survival increased for all cancers combined and between-country survival differences narrowed both for children and for adolescents/young adults.
Discussion
The two major -and encouraging -findings of our study are that survival for all cancers combined improved significantly across Europe (more for adolescents/young adults than for children) and that the survival gap between countries reduced. Considering individual cancers, survival increased significantly for leukaemias and PNET in children, and for non-Hodgkin lymphoma in adolescents/young adults. For all cancers combined, notable increases in survival were achieved by countries with poor survival in EURO-CARE-3 (i.e. Poland, the Czech Republic and Slovenia 14, 4 ); while for Northern Europe (with high survival in EURO-CARE-3) 5-year survival remained stable. Enrolment in clinical trials, development of international collaboration, access to effective protocols and development of health infrastructures/allocation of resources may all have contributed to the improved survival in Eastern Europe. 15 Although the survival improvement was most marked for adolescents/young adults, these older patients had significantly worse survival, in 2000-2002, than children for lymphoid leukaemia (50% versus 85%) and osteosarcoma (60% versus 77%) (compare Tables 3 and 5) . Survival was also lower in older patients for acute myeloid leukaemia, non-Hodgkin lymphoma and Ewing sarcoma, although none of these differences were statistically significant. In the earlier periods, survival was much higher for acute lymphoid leukaemia than for acute myeloid leukaemia, in both adolescents/young adults and children. 4 However, for adolescents/young adults, survival for acute myeloid leukaemia improved so much in 2000-2002 that it was higher than for acute lymphoid leukaemia. Fewer adolescent/young adult cancer patients participate in clinical trials than children, 16, 17 but this alone cannot explain worse survival: age is a major prognostic factor for several cancers, 3 and for similar cancers biological behaviour may differ with age. 3 There is a debate as to whether adolescents with cancer should be treated as children or adults.
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For acute lymphoblastic leukaemia, adolescents have better survival when treated with paediatric rather than adult protocols. 19, 20 This study took the opportunity of analysing survival for 15 rare cancers in children, defined as those with an incidence of <2 cases per million per year. 21 It was found that 5-year survival for rare cancers was generally good at P70%, but low for hepatic carcinoma (45%), adrenocortical carcinoma (60%) and chronic myeloproliferative disease (64%). The rarity of these malignancies renders clinical and biological research very difficult (rare tumours as almost never the object of clinical trials for example). However, studies coordinated by the Childhood Liver Tumours Strategy Group (SIO-PEL) have shown that international collaboration is feasible and that trials on rare cancers can be conducted successfully. 22 The Italian project on rare tumours in paediatric age (TREP) 21 is a national initiative in this area that has established a collaborative network of specialists and is developing diagnostic and therapeutic guidelines for individual rare cancers.
Variations in data quality and data comparability can vitiate comparison of cancer survival between populations. Major indicators of data quality are the proportion of DCO/ autoptic cases, proportion of cases lost to follow-up and proportion of cases microscopically verified. In the present study, the proportion of DCO cases was very low (typically 0%, overall 0.4%) and for three registries only it was in the range of 3-4% (Table 1) . With very few exceptions, registries followed their cases for at least 5 years. Six registries only had between 10% and 29% of cases with a follow-up of less than 5 years.
Microscopic confirmation was also high at 95% overall with only two registries conspicuously lower (range 68-80%) than the average. Microscopic confirmation is particularly important for childhood cancers, which are primarily classified by histologic type. CNS cancers had the lowest proportion of microscopic confirmation at 86%, and the figure was below 80% in three of the five geographical areas considered in this study: lowest (72%) in Eastern Europe, highest (95%) in Central Europe. This variability may bias inter-regional survival comparison since absence of microscopic verification may result in less well-tailored treatment and lower survival. In fact regional survival for CNS tumours was high in Central Europe where microscopic confirmation was high and was low in Eastern Europe where microscopic confirmation was low.
Another major indicator of data quality is the proportion of cases allocated to unspecified categories within a major diagnostic group. The number of unspecified cases among EUROCARE-4 children and adolescents/young adults was low overall at 3.8%. However, the Italian registries of Salerno and Trento had very high proportions of unspecified cases. As noted in Section 2, Thames and Denmark did not provide ICD-O morphology codes for any cancer (only ICD-10 classified data), and their data were excluded from several analyses.
Changes in cancer coding can impair the comparability of results between different time periods. EUROCARE-4 is the first EUROCARE study to use the latest (ICD-O-3) coding system. ICD-O-3 differs in several respects from previous editions, particularly as regards the classification of myelodysplastic syndromes, chronic myeloproliferative disease, polycythemia rubra vera, ovarian carcinomas of borderline malignancy, and pilocytic astrocytoma. For persons under 25 years, the most important of these changes is that pilocytic astrocytoma has been downgraded to borderline behaviour. This tumour accounts for about half the astrocytomas diagnosed in children and a quarter of those diagnosed in adolescents/young adults. The effects of this on survival estimates for astrocytoma and all CNS cancers are evident in Section 3 and should be borne in mind whenever results from different time periods are compared.
A disappointing aspect of the latest EUROCARE data is that countries from Eastern Europe are poorly represented. Although cancer registries from Poland and the Czech Republic participated, the national registries of Slovakia and Estonia -included in EUROCARE-3 -dropped out of EUROCARE-4 because local laws obstructed patient follow-up. This is undesirable particularly because the previous studies consistently indicated worse survival in Eastern European countries than in the rest of Europe. Cancer survival in patients under 25 years is particularly poorly documented in Eastern Europe, and cancer registration is far from attaining national coverage.
National registration should be a priority for these countries as an essential part of a policy for effective cancer control in Europe. Not only should full cancer registration and efficient outcome surveillance be promoted, but also initiatives to maintain and improve the quality of the collected data are also important (particularly morphology data in childhood and adolescent/young adult cancers). In some countries, privacy legislation impedes the collection of follow-up and mortality data. 14 The European Commission has an important role in promoting these policies and principles throughout Europe. To conclude, cancers are rare in people under 25 years, but unlike most rare cancers they can be effectively treated in the majority of cases. To ensure the best outcomes, young people who develop malignancies should be referred to specialistcare centres and treated in accordance with national or international protocols. Where such protocols are not available they should be developed. Multi-institutional co-operation and European inter-group co-operative studies have an important role to play in developing treatment protocols and also in organising and co-ordinating clinical research in these cancers.
